Table 1.
Clinical characteristics of included patients.
| Total cSVD Score | ||||||
|---|---|---|---|---|---|---|
| All (n = 263) | 0 n = 42) | 1 (n = 62) | 2 (n = 69) | 3 (n = 53) | 4 (n = 37) | |
| Age (Median, IQR) | 61 (51.0–70.0) | 46.5 (38.8–57) | 59.5 (48.0–66.3)* | 60.0 (53.0–71.0)* | 67.0 (59.5–73.0)* | 70.0 (60.5–81.0)* |
| Male, n (%) | 190 (72.2) | 29 (69.0) | 44 (71.0) | 52 (75.4) | 41 (77.4) | 24 (64.9) |
| NIHSS on admission (Median, IQR) | 5 (2–6) | 4.5 (3–6) | 4 (2–6) | 5 (2–6) | 4 (3–6) | 5 (2–6) |
| NIHSS at discharge (Median, IQR) | 2 (1–4) | 2.5 (1–4) | 2 (1–3) | 3 (1–5) | 2 (1–5) | 2 (1–4) |
| mRS at discharge (Median, IQR) | 0 (0–1) | 0 (0–1) | 0 (0–1) | 0 (0–2) | 0 (0–2) | 0 (0–1) |
| Delay from stroke onset to cSVD detection (Median, IQR) | 7 (5–8) | 7 (5–8) | 7 (5–8.75) | 7 (5–8) | 6 (5–8) | 7 (6–8) |
| Hypertension, n (%) | 173 (65.8) | 19 (45.2) | 35 (56.5) | 48 (69.5)* | 38 (71.7)* | 33 (89.2)* |
| Diabetes mellitus, n (%) | 89 (33.8) | 12 (28.6) | 18 (29.0) | 27 (39.1) | 22 (41.5) | 10 (27.0) |
| Hyperlipidemia, n (%) | 111 (42.2) | 22 (52.4) | 24 (38.7) | 31 (44.9) | 21 (39.6) | 13 (35.1) |
| Hyperhomocysteinemia, n (%) | 13 (4.9) | 3 (7.1) | 2 (3.2) | 4 (5.8) | 2 (3.8) | 2 (5.4) |
| Atrial Fibrillation, n (%) | 19 (7.2) | 2 (4.8) | 7 (11.3) | 4 (5.8) | 2 (3.8) | 4 (10.8) |
| History of stroke/TIA, n (%) | 44 (16.7) | 3 (7.1) | 7 (11.3) | 13 (18.8) | 11 (20.8) | 10 (27.0) |
| Alcohol consumption, n (%) | 41 (15.6) | 5 (11.9) | 5 (8.1) | 17 (24.6) | 5 (15.1) | 6 (16.2) |
| Current or former smoking, n (%) | 118 (44.9) | 20 (47.6) | 24 (38.7) | 40 (58.0) | 25 (47.2) | 9 (24.3) |
cSVD, cerebral small vessel disease; IQR, interquartile; NIHSS, national institute of health stroke scale; mRS, Modified Rankin Scale; TIA, transient ischemic attack.
*
P < 0.05, compared with group cSVD Score 0.